summari report sale
organ compar ex-fx basi came
ahead estim
consensu respect growth broad-bas
busi led diabet rtg restor therapi
group geographi growth led
emerg market geographi ex-fx also
strong margin perspect gross margin adj
oper margin y/i expans respect
translat non-gaap ep ex-fx
came consensu estim
ep out-performance also reflect benefit fx
tax rate guidanc front rais fy sale
guidanc organ vs previou guidanc
guid growth mdt guidanc
impli roughli growth vs growth
manag attribut primarili tougher prior year compar
bottom-lin left report ep guidanc unchang
ex-fx note compani
absorb addit advers impact mzor
acquisit china tariff ep guid
neutral impact fx
chang model increas fy sale estim
organ ex-fx increas fy
non-gaap ep estim report
maintain price target base
cy ep estim
 recap revenu organ
ahead estim consensu worth
note growth came well-abov mdt
guidanc repres sequenti acceler vs
growth report ep beat
consensu estim ep beat rel
model primarili reflect higher revenu higher gross margin
model vs estim lower tax rate
forecast vs estim partli off-set
higher opex vs estim oper
margin repres improv
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani data secur llc estim reuter
four divis exceed street expect cardiac vascular group cvg
sale organ beat consensu estim minim
invas therapi group mitg revenu grew organ beat consensu
forecast restor therapi group rtg sale increas organ
ahead consensu forecast diabet revenu rose organ better
consensu estim
crhf growth mix mdt crhf cardiac rhythm heart failur busi grew ex-fx
in-lin high power remain soft implant cardiovert
defibril crt-d cardiac resynchron therapi defibril global sale low-
singl digit high-single-digit respect low power ww pacemak crt-p cardiac
resynchron therapi pacemak high-single-digit mdt af atrial fibril solut
grew mid-teen diagnost reveal linq sale grew low-single-digit global
regard htwr lvad left ventricular assist devic declin mid-single-digit
csh growth led onyx evolut csh coronari structur heart revenu grew
organ modest deceler growth albeit difficult prior year
compar csh growth larg driven mid-teen growth transcathet aortic valv
replac tavr mid-single-digit growth de accord ou tavr grew
mid-teen behind continu uptak evolut de result reflect low growth
us driven continu strength resolut onyx launch
apv growth acceler apv aortic peripher vascular sale grew organ
acceler vs growth perform quarter reflect high-teen growth
endoven low double-digit growth dcb drug coat balloon low-singl digit growth aortic
note dcb sale declin low-single-digit growth ou excess ex-
pain franchis clear highlight rtg pain therapi sale grew y/i organ step
reflect mid growth spinal cord stimul low double-digit
growth pain pump low-single-digit growth intervent spine result driven
mid growth us led intelli overal estim ww sale
ex-fx includ us use mdt result estim global
market grew ex-fx in-lin level us market grew y/i
also in-lin y/i
spine neurovascular mix global spine sale ex-fx slightli better
compani deliv flattish growth core spine bmp bone
morphogenet protein core spine declin low-single-digit quarter
manag note segment combin enabl technolog grew y/i mdt
neurovascular busi grew mid-teen global includ growth mid-single-
digit ou growth estim neurovascular sale includ
mitg growth improv mitg sale total organ improv
growth driven acceler surgic innov si respiratori
gastrointestin renal specif si sale grew organ
continu strong perform advanc advanc stapl note continu
market convers minim invas surgeri mi contribut growth highlight mid-
teen si growth emerg market em sale grew organ meaning
growth driver includ high-singl digit growth patient monitor vs
low-singl digit growth due tough comp led nellcor puls oximetri low double-digit
growth gi vs mid-singl digit growth boost launch calibration-fre bravo
strong adopt endoflip region growth led emerg market ex-fx vs
us vs non-u develop market growth flattish compar
diabet sale y/i organ global diabet sale y/i organ
repres sequenti improv sequenti growth
led emerg market vs non-u develop market
vs us growth modestli weaker sequenti vs
recal recent reclassifi busi sub-seg advanc insulin manag
aim emerg technolog et aim deliv y/i growth second straight
quarter led demand minim hybrid close loop system increas sensor
attach rate us demand minim initi uptak outsid us
separ et deliv y/i growth versu y/i led us launch
guardian connect mid-jun continu glucos monitor cgm market full-year
continu expect diabet franchis grow low-to-mid teen includ high-singl
digit growth impli deceler growth larg relat prior year comp recal
neg growth last year due cgm capac constraint stronger growth
due increas capac catch addit anniversari
consum revenu warranti convers anima transit
bullish pipelin product remain track one key theme call
compani product pipelin manag character pipelin strongest
excit pipelin near histori re-affirmed time key upcom product
pump harmoni cgm diabet fiscal compani surgic
robot also expect fy
em growth acceler emerg market em revenu y/i ex-fx
acceler growth region eastern europ grew fastest
follow middl east africa south asia china southeast asia
overal em revenu account revenu last quarter
in-lin estim large-cap med-tech median em exposur worth note mdt em
growth large-cap med-tech median roughli
fy growth outlook rais ep guidanc re-affirmed earlier today rais fy
sale growth guidanc organ compar ex-fx basi continu
expect fx headwind fiscal impli report revenu rang
report mdt fy sale outlook busi follow cvg
expect grow /- mitg expect grow /- rtg expect grow
diabet expect grow low mid-teen also worth note manag said
feel comfort higher-end overal organ rang regard margin
continu target oper margin improv ex-fx fiscal increment
benefit fx impli report basi bottom-lin left
report ep guidanc unchang assum neutral fx impact headwind
mzor china tariff regard manag guid top-lin growth organ
compar ex-fx basi non-gaap ep expect fx neutral non-gaap
ep given fx tailwind ep impli roughli hit
larg cap med-tech organ revenu grow fastest pace sinc
report tuesday morn aggreg growth rate larg cap
med-tech name see figur analysi indic world-wide organ ex-fx growth acceler
sequenti mark fastest quarterli growth rate sinc
start analysi prior year comp rel easi growth
stack two-year basi highest level sinc began compil data
note organ growth adjust fx acquisitions/divestitur sell day meaning
note organ growth adjust fx acquisitions/divestitur sell day meaning
organ med-tech pf cfn average excl growth year stack med-tech pf cfn average excl medtron plc
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
plc incom statementin million except per share datafisc year end etot net currenc y-i expensesresearch oper incomenet interest expens amort incom tax incom adj continu year-to-year incom year-to-year incom dilut share year-to-year compani report secur llc estim medic technolog
